Cyclin-dependent kinase 6 Antibodies

Cyclin-dependent kinase 6 (CDK6)

Phosphorylates pRB/RB1 and NPM1. Interacts with D-type G1 cyclins during interphase in G1 to form a pRB/RB1 kinase and controls the entry into the cell cycle.

Involved in initiation and maintenance of cell cycle exit during cell differentiation; prevents cell proliferation and regulates negatively cell differentiation, but is necessary for the proliferation of specific cell types (e.g.

Gene Information

Human
Gene Name:	CDK6
Uniprot:	Q00534
Entrez:	1021

Family

Belongs to:
protein kinase superfamily

Alternative Names

Cell division protein kinase 6; cyclin-dependent kinase 6; EC 2.7.11; EC 2.7.11.22; PLSTIREMGC59692; Serine/threonine-protein kinase PLSTIRE

Molecular Weight

Mass (kDA):
36.938 kDA

Genomic Context

Human
Location:	7q21.2
Sequence:	7; NC_000007.14 (92604921..92836573, complement)

Tissue Specificity

Expressed ubiquitously. Accumulates in squamous cell carcinomas, proliferating hematopoietic progenitor cells, beta-cells of pancreatic islets of Langerhans, and neuroblastomas. Reduced levels in differentiating cells.

Subcellular Localizations

Cytoplasm. Nucleus. Cell projection, ruffle. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Localized to the ruffling edge of spreading fibroblasts. Kinase activity only in nucleus. Localized to the cytosol of neurons and showed prominent staining around either side of the nucleus (By similarity). Present in the cytosol and in the nucleus in interphase cells and at the centrosome during mitosis from prophase to telophase (PubMed:23918663).

Diseases

• Malignant Neoplasms
• Neoplasms
• Retinoblastoma
• Carcinoma
• Cell Transformation, Neoplastic
• Leukemia
• Malignant Paraganglionic Neoplasm
• Malignant Neoplasm Of Breast
• Mammary Neoplasms
• Growth Arrest
• Lymphoma
• Melanoma
• Malignant Squamous Cell Neoplasm

• Hyperplasia
• Adenocarcinoma
• Prostatic Neoplasms
• Malignant Neoplasm Of Prostate
• Carcinogenesis
• Malignant Neoplasm Of Lung
• Lung Neoplasms

Interacting Proteins

• CCND1
• CCND3
• CCNH
• CDC37
• CDKN1A

• CDKN1B
• CDKN2A
• CDKN2B
• CDKN2C
• CDKN2D

• HSP90AB1
• RUNX1

Pathways

• Cell Cycle
• Cell Proliferation
• Cell Cycle Arrest
• G1 Phase
• Cell Growth
• S Phase
• Cell Death
• Cell Division
• Senescence
• Pathogenesis
• Localization
• Induction Of Apoptosis
• Methylation

• Cell Differentiation
• Mitosis
• Dna Replication
• Oncogenesis
• Translation
• Protein Phosphorylation
• Hyperphosphorylation

PTMs

• Phosphorylation
• Methylation
• Cleavage
• Dephosphorylation
• Acetylation
• Ubiquitination

• Demethylation
• Reduction
• Phosphorothioation
• Nitrosylation
• Hydroxylation
• Glycosylation

Research Areas

• Cell Cycle and Replication
• Ovarian Carcinoma Cell Markers

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CDK6

Boster Bio - Best Uses Of The CDK6 Marker

When you're looking to make use of the CDK6 Marker scientists will be thrilled to learn that Boster Bio has a variety of applications for it. These applications can be utilized for specific species or for general purposes. Boster scientists will have the opportunity to submit their species-specific research results as well as receive product credits. These benefits apply to scientists from all over the world. Here are a few examples. Below are some of the most effective uses of the CDK6 marker.

Boster Bio Anti-Cyclin-dependent kinase 2 cdk2 antibody

The Boster Bio Anti-Cyclin-Dependent Kinase 2 (CDK2) antibody has been validated on multiple platforms and has high specificity and affinity for this protein. This antibody is developed for the detection of Cyclin-dependent Kinase 2 in human cells. This antibody reacts with Human Cyclin dependent kinases. It does not cross-react with other proteins.

The CDK assay was done following a previously published procedure. In particular, 500 mg of protein was extracted from cell lysates before being immunoprecipitated with an anti-CDK2 antibody. After this step, the immunocomplexes were washed twice with kinase buffer , and the final pellet was incubated at 37°C for 30 minutes.

To increase the effectiveness of immunoprecipitate CDK2 protein and to improve detection the anti-CDK2 antibodies had to be pre-incubated with salicylic acid. The anti-CDK2 antibody's immunoprecipitates were then used in an In Vitro Kinase Assay as well as an immunoblots to determine the activity of the protein. In this manner, the Boster Bio Anti-Cyclin-Dependent Kinase 2 antibody is an excellent choice for your research.

The anti-CDK2 antibody is able to recognize CDK2 and also bind to salicylic acid. Salicylic acid is a direct binder to CDK2, reducing its activity, and quenching its fluorescence. Studies on protein crystallization as well as mutations will confirm the affinity of Salicylic acid for CDK2.

Cancer is defined by the uncontrolled proliferation and division of mammalian cells. CDKs regulate the progression of cell cycles by ensuring that they have a regular exit from the cell cycle phases. If their activity is disrupted they let the cells get out of this control and undergo malignant transformation. The treatment of human malignancies could be a result of the suppression of CDKs. This antibody may be worth a trial. You can also examine the results of your own tests.

CDK2/cyclin B showed an activity that was linear, at 125 ng/well and a good dynamic range with cell growth of 250 ng/well. CDK2/cyclin B's RLU is 33586, while CDK2/cyclin C has a similar dynamic range. The RLU of CDK2/cyclinA at 125ng/well is an indication of an optimal concentration.

Applications

The CDK6 gene encodes a kinase that has dual purposes, with a specific structural role in erythroid cells. In erythroid cells, Cdk6 is tethered to the cytoskeletonand is in turn phosphorylated by unidentified proteins. It could also function as a stabilizing anchoring factor. Therefore, the Cdk6 gene has many applications.

One such marker is 66278-1-Ig which targets CDK6 WB and IF assays. It has been shown to be reactivity in both mouse and rat samples. These results are encouraging because it is possible to determine whether an agent will work better in certain patients, based on certain markers and their expression levels. More research is needed to further investigate the role of CDK6 within a variety of cancers.

The CDK4/6 protein is an important part of the cell cycle. CDC4/6 has been implicated in the development of many types of cancer. It regulates cell cycle transitions, from the prophase of DNA synthesis, to the S phase and mitosis. The G1-S transition is regulated by the cyclin-CDK4/6-retinoblastoma pathway. Since the CDK4/6 and cyclin D share 71 percent amino acid homology they can also interact with one another.

If CDK6 levels are high in expression and resistance to breast cancer cells could be increased by platinum. The resistance to platinum may be boosted by chemotherapy drugs that target receptors for CDK6 that encode for cells. By targeting the CDK6 gene, researchers studying cancer are able to test the possible role of CDK6 in the resistance to chemotherapy and radiation. These compounds could be the basis for chemotherapy for cancer, according the researchers.

Benefits

A CDK6 marker could be targeted to kill cancerous cells. This could result in many benefits, such as a lower risk of recurrence or better outcomes. Overexpression of CDK6 can result in increased resistance to inhibitors of CDK4/6. This could lead to an increase in the cost of treating cancer. The CDK6 marker could also help diagnose cancer and pinpoint the causes of cancer. Its advantages are explained below.

The function of other kinases is controlled by the gene CDK6 during the cancer cell cycle. For instance, it controls the production of proteins, such as the apoptosis. It also regulates cytokines involved in cell cycle progression. The CDK6 gene plays a key role in controlling the progression of G1-S phase of the cell cycle. It binds to the D-cyclins CYP1A, CYP3A. Both proteins regulate the cell cycle However, they play different roles.